MustGrow Sees Positive Results From Tobacco Field Trials

MustGrow Biologics (CSE: MGRO) this morning reported on results for the use of its mustard-based biopesticide within tobacco field trials. The study was focused on comparing the efficacy of its product with that of the synthetic chemical chloropicrin, a leading soil fumigation synthetic chemical.

Field trial results, which were conducted by a third part research organization, found that MustGrow’s biopesticide has comparable efficacy and yield results versus the synthetic chemical. The study specifically focused on plant growth, phytotocixitity, nematodes, and soil fungi, with the overall results being comparable. Further evaluation is being conducted once the tobacco leaves have been cured.

Field trial data collected by the third party will be used to potentially achieved product registration for the use of MustGrow’s biopesticide against diseases and insect pests in tobacco cultivation. The $28 billion industry is currently rife with opportunity for natural biopesticides as synthetic chemicals continue to be banned or deregistered, leaving farmers with few crop protection options.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

The product is to continue to be evaluated in its effectiveness over the 2021 growing season to assess leaf yield and chemistry data once the tobacco leaves have been cured.

MustGrow Biologics last traded at $2.00 on the CSE.


FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

8 Mining Stocks Our Viewers Asked Us to Review | Sept 14th-18th

Canada Is Finally Fast-Tracking New Mines | John Passalacqua – First Phosphate

Gold & Silver Just Added $2 Billion to This Project | Aya Gold – Bourmadine PEA

Recommended

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Japan Gold Lands $50 Million in Committed Capital Through Solidcore Alliance

Related News

Curing The Banana Panama Disease – The Daily Dive feat Colin Bletsky of MustGrow Biologics

Kickstarting our short holiday week for the Daily Dive is that of Colin Bletsky, COO...

Monday, December 21, 2020, 01:00:00 PM

MustGrow Biologics Files Patents For Bio-Herbicide

MustGrow Biologics Corp (CSE: MGRO) announced this morning that it has filed a number of...

Monday, January 27, 2020, 08:57:52 AM

MustGrow Enters Exclusive Marketing And Distribution Agreement With NexusBioAg

MustGrow Biologics (CSE: MGRO) has seen further validation of its tech this morning, with the...

Wednesday, July 20, 2022, 08:23:29 AM

MustGrow Biologics Updates Market On Its Biopesticide Product Pipeline

MustGrow Biologics (CSE: MGRO) this morning provided an update to the market on the status...

Wednesday, December 9, 2020, 07:22:59 AM

MustGrow Biologics: Three Things To Know

MustGrow Biologics (CSE: MGRO) has been on a high volume tear as of late, with...

Wednesday, February 19, 2020, 12:21:45 PM